Videos

Bispecifics in MM: mSMART Guidelines for Monitoring and Managing AEs

Key opinion leaders in multiple myeloma management address barriers inherent in the selection and use of bispecifics.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

Pharmacists’ Perspectives on Initiating Bispecific Therapy in Multiple Myeloma

Focused discussion on the mSMART guidelines for monitoring and managing adverse events associated with bispecific therapies in patients being treated for relapsed/refractory multiple myeloma.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

Insights from Experts at Mayo Clinic: Step-up and Treatment Dosing of Bispecifics

Experts Scott A. Soefje, PharmD, and Kirollos S. Hanna, PharmD, share their perspectives on initial steps in initiating bispecific therapy for patients with multiple myeloma.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

Subset Analysis of the MAIA Study in the Frail Multiple Myeloma Population

A panel of key opinion leaders from Mayo Clinic reflect on optimizing use of bispecifics in relapsed/refractory multiple myeloma, reviewing step-up dosing, administration, and followup strategies.

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

Treatment Approaches in Patients With Transplant-Ineligible NDMM

Experts comment on the subset analysis of the MAIA study in the frail NDMM patient population.

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

Clinical Insights on the Treatment of Patients with High-Risk MDS

Noffar Bar, MD, discusses the MAIA study investigating a daratumumab combination therapy in patients with transplant-ineligible multiple myeloma.

An Introduction to MDS: Initial Diagnosis and Patient Risk Stratification

Dr. Daver reviews treatment goals and treatment options for patients with higher-risk MDS.

Positive Brexu-Cel Findings Raise Questions of Treatment Sequencing in B-ALL

Naval G. Daver, MD introduces myelodysplastic syndrome (MDS), focusing on the typical disease course, role of biomarker testing and risk stratification.

$Gregory W. Roloff, MD, indicates that brexucabtagene autoleucel did not yield significant positive findings in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who were MRD positive.$

Gregory W. Roloff, MD

June 25th 2023

Gregory W. Roloff, MD, indicates that brexucabtagene autoleucel did not yield significant positive findings in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who were MRD positive.

DEAR Study Offers ‘Hope’ to Patients With Non-Metastatic CRPC

Alicia K. Morgans, MD

Overview of Treatment Options for Relapsed/Refractory Multiple Myeloma

Alicia K. Morgans, MD, MPH, from Dana-Farber Cancer Institute indicates that patients with non-metastatic castration-resistant prostate cancer are able to stay on treatment for long periods of time with darolutamide vs enzalutamide and apalutamide.

Thomas G. Martin, MD;Ajay K. Nooka, MD;Jeremy Larsen, MD

Determining Transplant Ineligibility in Newly Diagnosed Multiple Myeloma

Key opinion leaders share comprehensive insight to the treatment armamentarium for patients with relapsed/refractory multiple myeloma.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Features of High-Risk Multiple Myeloma and Clinical Trial Landscape

Focused discussion on factors that aid in determining transplant ineligibility when a patient presents with newly diagnosed multiple myeloma.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Treatment Options for Frontline and Relapsed Multiple Myeloma

The expert panel provides clinical insights on the key features of high-risk multiple myeloma and a look toward the clinical trial landscape.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Overview of Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

An overview of multiple myeloma treatment options in the frontline and relapsed settings.

Thomas G. Martin, MD;Ajay K. Nooka, MD;Jeremy Larsen, MD

What is the Role of Transplant in Treating Patients With NDMM?

Experts Thomas Martin, MD; Ajay Nooka, MD; and Jeremy Larsen, MD, provide a broad overview of cytokine release syndrome as it relates to the management of multiple myeloma.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Patient Monitoring and Workup in Relapsed MM

Key opinion leaders in multiple myeloma management reflect on the current role of stem cell transplant in patients with newly diagnosed disease.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Role of Transplant in Multiple Myeloma

Experts on multiple myeloma discuss approaches to laboratory workup and patient monitoring at the time of relapse.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Physician Assistant Details Importance of AE Management in Follicular Lymphoma

Clinical experts examine the role of transplant in multiple myeloma and discuss key clinical trials and the impact of adding daratumumab to triplet therapy.

The education of patients on identifying and reporting adverse effects is a critical part of effective toxicity management.

Jennifer L. Garson, PA-C

Clinical Implications from the MAIA and SWOG S0777 Studies

The education of patients on identifying and reporting adverse effects is a critical part of effective toxicity management.

Joselle Cook, MBBS, Mayo Clinic;Matthew James Pianko, MD

Clinical Insights from the Results of the MASTER Trial

A summary of updates from the MAIA and SWOG S0777 studies, with a focus on efficacy and tolerability data.

Luciano Costa, MD, PhD;Timothy Schmidt, MD

Goals of Therapy and Treatment Options for Patients with Transplant-Ineligible NDMM

Thoughtful discussion centered around recently presented updates to the MASTER trial.

Joselle Cook, MBBS, Mayo Clinic;Matthew James Pianko, MD

When to Perform Molecular Testing in Relapsed AML

Joselle Cook, M.B.B.S and Matthew James Pianko, MD discuss available treatment options and goals of therapy for patients with transplant-ineligible NDMM.

Naval Daver, MD;Harry P. Erba, MD, PhD;Dan Pollyea, MD, MS;Eunice S. Wang, MD

An Introduction to NDMM: Treatment Options and Patient Risk Stratification

Harry P. Erba, MD, PhD, discusses the need to retest for mutations including IDH1, IDH2, FLT3, NPMI, and KMT2A rearrangement for patients with relapsed or refractory acute myeloid leukemia.

Luciano Costa, MD, PhD;Timothy Schmidt, MD

Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple Myeloma

Luciano Costa, MD, PhD and Timothy Schmidt, MD introduce treatment regimen options and risk stratification for patients with transplant-eligible NDMM.

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

The Role of Molecular Testing in Diagnosing Acute Myeloid Leukemia

Closing out their discussion, the panel shares remaining unmet needs in the treatment of newly-diagnosed and relapsed multiple myeloma.

Naval Daver, MD;Harry P. Erba, MD, PhD;Dan Pollyea, MD, MS;Eunice S. Wang, MD